These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14663535)

  • 21. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis.
    Stegeman BH; de Bastos M; Rosendaal FR; van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
    BMJ; 2013 Sep; 347():f5298. PubMed ID: 24030561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effect on acne with a combiphasic desogestrel-containing oral contraceptive and a preparation containing cyproterone acetate.
    Vartiainen M; de Gezelle H; Broekmeulen CJ
    Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):46-53. PubMed ID: 11334476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate.
    Palombo-Kinne E; Schellschmidt I; Schumacher U; Gräser T
    Contraception; 2009 Apr; 79(4):282-9. PubMed ID: 19272497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and hormonal effects of the combination gonadotrophin-releasing hormone agonist plus oral contraceptive pills containing ethinyl-oestradiol (EE) and cyproterone acetate (CPA) versus the EE-CPA pill alone on polycystic ovarian disease-related hyperandrogenisms.
    Acién P; Mauri M; Gutierrez M
    Hum Reprod; 1997 Mar; 12(3):423-9. PubMed ID: 9130733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Smoking and use of oral contraceptives: impact on thrombotic diseases.
    Lidegaard O
    Am J Obstet Gynecol; 1999 Jun; 180(6 Pt 2):S357-63. PubMed ID: 10368521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick S; Kaye JA; Li L; Jick H
    Contraception; 2007 Jul; 76(1):4-7. PubMed ID: 17586129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database.
    Seaman HE; Langley SE; Farmer RD; de Vries CS
    BJU Int; 2007 Jun; 99(6):1398-403. PubMed ID: 17537215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risks of venous thromboembolic disease among German women using oral contraceptives: a database study.
    Farmer RD; Todd JC; Lewis MA; MacRae KD; Williams TJ
    Contraception; 1998 Feb; 57(2):67-70. PubMed ID: 9589831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of cyproterone acetate/ethinylestradiol in polycystic ovary syndrome: rationale and practical aspects.
    Ruan X; Kubba A; Aguilar A; Mueck AO
    Eur J Contracept Reprod Health Care; 2017 Jun; 22(3):183-190. PubMed ID: 28463030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-time use of newer oral contraceptives and the risk of venous thromboembolism.
    Suissa S; Blais L; Spitzer WO; Cusson J; Lewis M; Heinemann L
    Contraception; 1997 Sep; 56(3):141-6. PubMed ID: 9347203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 1995 pill scare revisited: anatomy of a non-epidemic.
    Spitzer WO
    Hum Reprod; 1997 Nov; 12(11):2347-57. PubMed ID: 9436662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in the use of combined oral contraceptives amongst women with and without acne.
    Seaman HE; de Vries CS; Farmer RD
    Hum Reprod; 2003 Mar; 18(3):515-21. PubMed ID: 12615817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-use risks.
    Rowe TC
    CMAJ; 2003 May; 168(11):1394. PubMed ID: 12771065
    [No Abstract]   [Full Text] [Related]  

  • 34. Incidence of Venous Thromboembolism in Transgender Women Receiving Oral Estradiol.
    Arnold JD; Sarkodie EP; Coleman ME; Goldstein DA
    J Sex Med; 2016 Nov; 13(11):1773-1777. PubMed ID: 27671969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
    Dinger J; Möhner S; Heinemann K
    Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy.
    Penning-van Beest FJA; Bezemer ID; Smits E; García Rodríguez LA; Cea Soriano L; Lapi F; Simonetti M; Asiimwe A; Herings RMC
    Contraception; 2020 Oct; 102(4):243-245. PubMed ID: 32470466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient acceptability and satisfaction with Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension).
    Shulman LP; Oleen-Burkey M; Willke RJ
    Contraception; 1999 Oct; 60(4):215-22. PubMed ID: 10640168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Superficial venous disease and combined hormonal contraceptives: a systematic review.
    Tepper NK; Marchbanks PA; Curtis KM
    Contraception; 2016 Sep; 94(3):275-9. PubMed ID: 25835269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety of a new oral contraceptive containing drospirenone.
    Heinemann LA; Dinger J
    Drug Saf; 2004; 27(13):1001-18. PubMed ID: 15471507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.